A C.D.C. panel recommends other vaccines over J.&J.
The agency’s advisers cited concerns about the increased incidence of a rare but potentially serious blood clotting condition among those who received the company’s shot.
F.D.A. Will Attach Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine
Federal regulators concluded that the risk of developing the syndrome was low, and that the benefits of the vaccine still strongly outweigh it.